Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (4188)	5/2/1998 4:56:00 PM
From: Mike Hagerty	Read Replies (1) of 6136

In Dick Davis Digest this week end: "Agouron Pharmaceutical (AGPH 36 OTC) reported financial results for their fiscal 1998 third quarter," notes Jim McCamant (Medical Technology Stock Letter). "Net income was $0.41 per share compared to a net loss of $0.18 per share in 1997. Sales of Viracept continue to increase. Since the drug was launched in March of last year, Viracept sales totaled over $300 million. This makes Viracept number one all-time in terms of the first twelve months of sales of any product from a biotech company. Agouron is a buy under 40."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next